Evolus Dirección

Dirección controles de criterios 3/4

Evolus' El consejero delegado es David Moatazedi , nombrado en May 2018, tiene un mandato de 5.58 años. la remuneración anual total es $3.60M , compuesta por 16.6% salario y 83.4% primas, incluidas acciones y opciones de la empresa. posee directamente 0.028% de las acciones de la empresa, por valor de $151.45K . La antigüedad media del equipo directivo y del consejo de administración es de 3.6 años y 5.8 años respectivamente.

Información clave

David Moatazedi

Chief Executive Officer (CEO)

US$3.6m

Compensación total

Porcentaje del salario del CEO	16.6%
Permanencia del CEO	5.9yrs
Participación del CEO	0.2%
Permanencia media de la dirección	2.4yrs
Promedio de permanencia en la Junta Directiva	6.2yrs

Actualizaciones recientes de la dirección

Recent updates

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Mar 20

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 10

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Jan 18

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Jan 18

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Jun 16

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Nov 06

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Sep 21

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de David Moatazedi en comparación con los beneficios de Evolus?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$62m
Sep 30 2023	n/a	n/a	-US$63m
Jun 30 2023	n/a	n/a	-US$66m
Mar 31 2023	n/a	n/a	-US$72m
Dec 31 2022	US$4m	US$597k	-US$74m
Sep 30 2022	n/a	n/a	-US$79m
Jun 30 2022	n/a	n/a	-US$79m
Mar 31 2022	n/a	n/a	-US$71m
Dec 31 2021	US$4m	US$572k	-US$47m
Sep 30 2021	n/a	n/a	-US$139m
Jun 30 2021	n/a	n/a	-US$131m
Mar 31 2021	n/a	n/a	-US$137m
Dec 31 2020	US$3m	US$527k	-US$163m
Sep 30 2020	n/a	n/a	-US$67m
Jun 30 2020	n/a	n/a	-US$82m
Mar 31 2020	n/a	n/a	-US$99m
Dec 31 2019	US$2m	US$550k	-US$90m
Sep 30 2019	n/a	n/a	-US$88m
Jun 30 2019	n/a	n/a	-US$73m
Mar 31 2019	n/a	n/a	-US$52m
Dec 31 2018	US$6m	US$362k	-US$47m

Compensación vs. Mercado: La compensación total de David ($USD3.60M) es aproximadamente el promedio para empresas de tamaño similar en el mercado US ($USD3.30M).

Compensación vs. Ingresos: La compensación de David ha aumentado mientras la empresa no es rentable.

CEO

David Moatazedi (45 yo)

5.9yrs

Permanencia

US$3,599,590

Compensación

Mr. David Moatazedi is Independent Director at Biomerica Inc. from December 07, 2022. He has been the President, Chief Executive Officer and Director of Evolus, Inc. since joining it on May 6, 2018. Mr. Mo...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
David Moatazedi	President	5.9yrs	US$3.60m	0.20% $ 1.4m
Sandra Beaver	Chief Financial Officer	1.6yrs	US$1.83m	0.037% $ 263.1k
Rui Avelar	Chief Medical Officer and Head of Research & Development	10.3yrs	US$1.26m	0.31% $ 2.2m
Nareg Sagherian	Head of Global Investor Relations & Corporate Communications	less than a year	sin datos	sin datos
Jeffrey Plumer	General Counsel	no data	sin datos	sin datos
Kurt Knab	Vice President of Sales	5.5yrs	sin datos	sin datos
Tomoko Yamagishi-Dressler	Chief Marketing Officer	less than a year	sin datos	sin datos
Jessica Novak	Senior Vice President of Human Resources	2.4yrs	sin datos	sin datos

2.4yrs

Permanencia media

45yo

Promedio de edad

Equipo directivo experimentado: EOLSEl equipo directivo de la empresa se considera experimentado (3.6 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
David Moatazedi	President	5.9yrs	US$3.60m	0.20% $ 1.4m
David Gill	Independent Director	6.2yrs	US$240.20k	0.062% $ 436.5k
Simone Blank	Director	6.3yrs	US$210.70k	0.89% $ 6.3m
Robert Hayman	Independent Director	6.3yrs	US$225.70k	0.096% $ 677.5k
Vikram Malik	Chairman of the Board	6.3yrs	US$247.70k	0.43% $ 3.1m
Karah Parschauer	Independent Director	4.8yrs	US$238.20k	0.051% $ 360.2k
Brady Stewart	Independent Director	2.3yrs	US$275.00k	0.073% $ 516.6k

6.2yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de EOLS se considera experimentada (5.8 años de antigüedad promedio).

Evolus Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Evolus, Inc. Announces Board Changes

President recently sold US$1.3m worth of stock

Independent Director notifies of intention to sell stock

Evolus, Inc. Appoints Nareg Sagherian as Head of Global Investor Relations and Corporate Communications

President recently sold US$822k worth of stock

President notifies of intention to sell stock

Recent updates

Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau

Evolus, Inc. Announces Board Changes

President recently sold US$1.3m worth of stock

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Evolus, Inc. has completed a Follow-on Equity Offering in the amount of $50.00478 million.

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Price target increased by 7.6% to US$22.29

Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024

Evolus, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Independent Director notifies of intention to sell stock

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Evolus, Inc. Announces Earnings Guidance for 2024

Evolus, Inc. Appoints Nareg Sagherian as Head of Global Investor Relations and Corporate Communications

New minor risk - Shareholder dilution

President recently sold US$822k worth of stock

President notifies of intention to sell stock

New minor risk - Insider selling

No longer forecast to breakeven

Evolus, Inc. Raises Earnings Guidance for the Full Year 2023

Price target increased by 12% to US$20.25

Evolus, Inc. Announces Results from the Phase 2 Clinical Study Evaluating the "Extra- strength" 40U Dose for Extended Duration of Jeuveau

Evolus, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Evolus, Inc. Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

President recently sold US$152k worth of stock

Evolus, Inc. Unveils New Branding for Product Jeuveau to Reflect Growing and Evolving Consumers

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Share price stability

Evolus, Inc. Revises Revenue Guidance for the Year 2023

Evolus Launches Nuceiva (Botulinum Toxin Type A) in Italy

Evolus Announces Successful Completion of Phase 2 Study Evaluating "Extra-Strength" Dose of Jeuveau (R)

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Price target increased by 9.4% to US$18.11

Consensus EPS estimates fall by 46%

Price target increased by 8.4% to US$17.22

Evolus, Inc. Provides Revenue Guidance for the Year 2023

Evolus, Inc. to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings: EPS misses analyst expectations

Evolus, Inc. Announces "Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase Ii Data Results, Representing Prolonged 6-Month Performance

Evolus, Inc. Receives Regulatory Approval for Nuceiva® in Australia

Evolus, Inc. Provides Earnings Guidance for the Year 2023

Forecast to breakeven in 2025

Insufficient new directors

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Evolus, Inc. Provides Earnings Guidance for the Full Year 2022

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Evolus: Turning That Frown Upside Down

Independent Director recently bought US$91k worth of stock

Evolus, Inc. Names Sandra Beaver as Its Chief Financial Officer, Effective September 5, 2022

Evolus appoints Experian's exec as CFO

Consensus forecasts updated

Forecast to breakeven in 2024

Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Second quarter 2022 earnings: Revenues exceed analyst expectations

Evolus, Inc. Reaffirms Revenue Guidance for Full Year 2022

Insufficient new directors

Evolus Q2 2022 Earnings Preview

Evolus, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Evolus, Inc. Completes Patient Enrollment in Phase II Clinical Study Evaluating Extra-Strength Dose of Jeuveau

Evolus, Inc. Announces Dermatologic Surgery Published A New Post Hoc Analysis of Its Phase III Studies Comparing Millennial Patients to Non-Millennials

Independent Director notifies of intention to sell stock

Independent Director recently sold US$138k worth of stock

Evolus, Inc. Revises Earnings Guidance for the Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau

Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?